Burn News and Research

RSS

Amsterdam Molecular Therapeutics provides third-quarter 2009 business updates

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive. This report summarizes material events and AMT's financial position for the third quarter of 2009.

18 Nov 2009

Pet therapy can have a positive effect on patients’ physical and psychosocial well being

Adults who use pet therapy while recovering from total joint-replacement surgery require 50 percent less pain medication than those who do not. These findings were presented at the 18th Annual Conference of the International Society of Anthrozoology and the First Human Animal Interaction Conference (HAI) in Kansas City, Mo.

17 Nov 2009

First-quarter fiscal 2010 results announced by IsoRay

IsoRay Inc. a medical isotope company focusing on the treatment of prostate, lung, head and neck and other malignant disease through the use of its proprietary radioisotope technology, announced its financial results for the first quarter of fiscal year 2010, ended September 30, 2009.

16 Nov 2009

Amorfix Life Sciences reports operating results for the three months ended September 30, 2009

Amorfix Life Sciences, a company focused on misfolded protein diseases, today reported its second quarter operating results and provided an update on the Company's diagnostic and therapeutic programs.

13 Nov 2009

Galapagos third quarter 2009 financial results in line with management expectations

Galapagos NV announces today that third quarter 2009 operational and financial results were in line with management expectations. These results encourage the Company to retain full year guidance of EUR 100 million revenues, a growth of 30% compared to 2008. Galapagos' service division BioFocus will significantly increase its cash contribution to the Group result for the full year 2009.

13 Nov 2009

Laser expert develops new technique for hair removal in ethnic skin types

Dr. Jay Kulkin, MD, internationally recognized laser expert and Fellow of the American Society for Laser Medicine and Surgery (highest designation), has successfully developed a laser technique making laser hair removal burns in ethnic skin types a thing of the past.

13 Nov 2009

Positive results from Puricore's Vashe Wound Therapy efficacy trial

PuriCore, the life sciences company focused on developing and commercializing proprietary solutions that safely, effectively, and naturally kill infectious pathogens, today announced results of a randomized clinical trial showing the potential effectiveness of its Vashe Wound Therapy in the post-operative care of split-thickness skin grafts for burn injuries.

11 Nov 2009

Tips to cut calories before Christmas time

It's official, everyone is getting ready for the Christmas Party Season. Research published this week from British Lion Eggs stated that 6 out of 10 women will be slimming down to fit into those LBDs from now until December in order to look their very shimmering best!

11 Nov 2009

New mapping technology to treat patients with heart rhythm disorders

Physicians with California Pacific Medical Center are among the first in the nation to use a new advanced mapping technology to help treat patients suffering from debilitating and potentially dangerous heart rhythm disorders.

11 Nov 2009

Common myths about sun exposure, sunscreen and vitamin D

When it comes to vitamin D, consumers are bombarded with mixed messages about the best source for this essential nutrient. While some may argue that small doses of intentional sun exposure are safe, dermatologists point out that the risk of developing skin cancer from ultraviolet (UV) radiation far outweighs the benefit of stimulating vitamin D production - particularly when enriched foods and supplements are safe and effective sources of this vitamin.

11 Nov 2009

GeoVax Labs announces financial results and operational update for the third quarter of 2009

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2009 financial results and provided an operational update.

6 Nov 2009

Third-quarter 2009 financial results announced by Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the three and nine months ended September 30, 2009.

6 Nov 2009

Thermal Energy receives $10 million in federal stimulus funding

Thermal Energy Corp. (TECO) in Houston announced today that it will receive $10 million in federal stimulus funding for its new combined heat and power project at the Texas Medical Center, where TECO provides district heating and cooling service to 18 institutions.

6 Nov 2009

Neurogen announces financial results for the third quarter of 2009

Neurogen Corporation, a drug development company historically focused on drugs for psychiatric and neurological disorders, today announced financial and operating results for the quarter ended September 30, 2009.

6 Nov 2009

Abiomed reports second quarter fiscal 2010 results

Abiomed, Inc., a leading provider of breakthrough heart support technologies, today announced second quarter fiscal 2010 revenue of $20 million.

5 Nov 2009

Stereotaxis reports $13.3 million revenue for third quarter 2009

Stereotaxis, Inc. today reported strong revenue growth, a significant increase in the gross margin, lower operating expenses and a significant reduction in the net loss for both the quarter and the nine month period ended September 30, 2009.

5 Nov 2009

Shionogi files New Drug Application in Japan

BioCryst Pharmaceuticals, Inc. today announced that its partner, Shionogi & Co., Ltd. has filed a New Drug Application (NDA) in Japan to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza. As a consequence of this filing, BioCryst will receive a regulatory milestone payment of $7 million under its agreement with Shionogi.

4 Nov 2009

Arrowhead Research updates its shareholders

Arrowhead Research Corporation’s (NASDAQ: ARWR) President and Chief Executive Officer today issued the following letter to the Company’s shareholders.

3 Nov 2009

Puricore reports increase in sales of 25% in Q3

PuriCore, the life sciences company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, today issues an Interim Management Statement covering the three-month and nine-month periods ending September 30, 2009.

3 Nov 2009

Gruve, an activity-based weight management solution from Muve

Muve, Inc., the activity-based weight management company, continues to see increased interest in measurable, sustainable wellness solutions by employers trying to reduce employee health care costs. Muve’s product, the Gruve Solution, helps corporate clients and their employees to become more healthy and productive, while reducing health care costs through measurable results.

29 Oct 2009